User contributions
Jump to navigation
Jump to search
- 12:55, 20 April 2024 diff hist +3 m Head and neck cancer Text replacement - "Reported efficacy based" to "Reported efficacy is based" current
- 12:54, 20 April 2024 diff hist +3 m Peripheral T-cell lymphoma Text replacement - "Reported efficacy based" to "Reported efficacy is based" current
- 17:14, 16 April 2024 diff hist -1 m ASCO guidelines Text replacement - "old-prod.asco.org" to "society.asco.org" current
- 20:16, 15 April 2024 diff hist 0 Classical Hodgkin lymphoma, pediatric
- 20:07, 15 April 2024 diff hist -1 Hepatoblastoma current
- 20:04, 15 April 2024 diff hist -29 Rhabdomyosarcoma, pediatric →Low Risk current
- 20:03, 15 April 2024 diff hist +17 Rhabdomyosarcoma, pediatric →Intermediate Risk
- 20:01, 15 April 2024 diff hist -16 Gestational trophoblastic neoplasia current
- 19:59, 15 April 2024 diff hist 0 Rhabdomyosarcoma, pediatric - historical current
- 19:57, 15 April 2024 diff hist +17 Rhabdomyosarcoma, pediatric →High Risk
- 19:57, 15 April 2024 diff hist +18 Neuroblastoma - historical →High Risk current
- 12:19, 3 April 2024 diff hist 0 m Breast cancer, HER2-positive Text replacement - "PRO Analysis:" to "PRO analysis:"
- 12:17, 3 April 2024 diff hist 0 m Light-chain (AL) amyloidosis Text replacement - "HRQoL Analysis:" to "HRQoL analysis:"
- 23:43, 27 March 2024 diff hist +994 Editorial Board current
- 23:31, 27 March 2024 diff hist -285 Editorial board transclusions →Plasma cell dyscrasia current
- 00:42, 27 March 2024 diff hist 0 m Testicular cancer Text replacement - "cycles, given" to "cycles; given"
- 00:42, 27 March 2024 diff hist 0 m Multiple myeloma - historical Text replacement - "cycles, given" to "cycles; given"
- 00:42, 27 March 2024 diff hist 0 m Multiple myeloma, induction Text replacement - "cycles, given" to "cycles; given"
- 00:42, 27 March 2024 diff hist 0 m Light-chain (AL) amyloidosis Text replacement - "cycles, "given" to "cycles; "given"
- 00:41, 27 March 2024 diff hist 0 m Diffuse large B-cell lymphoma - historical Text replacement - ", next cycle to start" to "; next cycle to start"
- 00:40, 27 March 2024 diff hist 0 m Anaplastic large cell lymphoma Text replacement - ", next cycle to start" to "; next cycle to start" current
- 00:39, 27 March 2024 diff hist -1 m Hepatoblastoma Text replacement - "21-day course (to be given within 42 days of resection)" to "21-day course; to be given within 42 days of resection"
- 00:38, 27 March 2024 diff hist +10 m Classical Hodgkin lymphoma Text replacement - "21- to 28-day cycles (depending on degree of myelosuppression)" to "21- to 28-day cycles; cycle length depends on degree of myelosuppression"
- 00:37, 27 March 2024 diff hist 0 m Colorectal cancer Text replacement - "14-day cycle for up to 6 cycles, then proceed to sLV5FU2:" to "14-day cycle for up to 6 cycles; then proceed to sLV5FU2:"
- 00:27, 27 March 2024 diff hist -32 m Acute promyelocytic leukemia Text replacement - "One course of up to 90 days" to "Up to 90-day course"
- 00:27, 27 March 2024 diff hist -8 m Acute promyelocytic leukemia Text replacement - "One course of up to 60 days" to "Up to 60-day course"
- 11:29, 26 March 2024 diff hist 0 m Colon cancer - historical Text replacement - "14-day cycle for 12 cycles, to start within 10 weeks of surgery" to "14-day cycle for 12 cycles; to start within 10 weeks of surgery" current
- 11:28, 26 March 2024 diff hist 0 m Rhabdomyosarcoma, pediatric - historical Text replacement - "12-week cycle for 4 cycles, beginning on weeks 0, 12, 24, 36" to "12-week cycle for 4 cycles; beginning on weeks 0, 12, 24, 36"
- 11:08, 13 March 2024 diff hist -9 Multiple myeloma, relapsed-refractory →Glucocorticoid therapy
- 13:59, 4 March 2024 diff hist 0 Editorial Board
- 13:30, 4 March 2024 diff hist +42 Main Page current
- 13:52, 1 March 2024 diff hist +3 Pancreatic cancer
- 13:51, 1 March 2024 diff hist 0 Glioblastoma
- 13:51, 1 March 2024 diff hist +3 Esophageal cancer
- 13:50, 1 March 2024 diff hist 0 Esophageal adenocarcinoma
- 13:50, 1 March 2024 diff hist 0 Classical Hodgkin lymphoma, pediatric
- 13:50, 1 March 2024 diff hist -2 Allogeneic HSCT
- 13:35, 1 March 2024 diff hist +3 m Low-grade glioma - null regimens Text replacement - "4 Gy" to "400 cGy"
- 13:35, 1 March 2024 diff hist +3 m Mantle cell lymphoma Text replacement - "4 Gy" to "400 cGy"
- 13:35, 1 March 2024 diff hist +3 m High-grade glioma, pediatric Text replacement - "4 Gy" to "400 cGy"
- 13:35, 1 March 2024 diff hist +18 m Small cell lung cancer Text replacement - "4 Gy" to "400 cGy"
- 13:35, 1 March 2024 diff hist +6 m Glioblastoma Text replacement - "4 Gy" to "400 cGy"
- 13:35, 1 March 2024 diff hist +3 m Gallbladder cancer Text replacement - "4 Gy" to "400 cGy"
- 13:35, 1 March 2024 diff hist +3 m Pancreatic cancer Text replacement - "4 Gy" to "400 cGy"
- 13:35, 1 March 2024 diff hist +3 m CNS leukemia Text replacement - "4 Gy" to "400 cGy"
- 13:35, 1 March 2024 diff hist +9 m Follicular lymphoma Text replacement - "4 Gy" to "400 cGy"
- 13:34, 1 March 2024 diff hist +3 m Cholangiocarcinoma Text replacement - "4 Gy" to "400 cGy"
- 13:34, 1 March 2024 diff hist +27 m Classical Hodgkin lymphoma Text replacement - "4 Gy" to "400 cGy"
- 13:34, 1 March 2024 diff hist +39 m Bladder cancer Text replacement - "4 Gy" to "400 cGy"
- 13:34, 1 March 2024 diff hist +15 m Esophageal cancer Text replacement - "4 Gy" to "400 cGy"